Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Epiduo (adapalene and benzoyl peroxide) Gel, 0.1% / 2.5%. Watson's ANDA product is a generic version of Galderma Laboratories, L.P. Epiduo® Gel is a topical ointment prescription drug that combines a retinoid (adapalene) and an antimicrobial (benzoyl peroxide) for the treatment of acne vulgaris (severe acne) in people who are at least 12 years old.
Perrigo Company announced that it has received final approval from the U.S.
Cipher Pharmaceuticals Submits NDA Amendment For CIP-ISOTRETINOIN
Published Date: November 23, 2011 07:00:00 AM EST
Toronto Stock Exchange Symbol: DND